Overview

  • Product nameAnti-EGFR (phospho Y845) antibodySee all EGFR primary antibodies ...
  • Description
    Rabbit polyclonal to EGFR (phospho Y845)
  • Tested applicationsICC/IF, WB, ICCmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic phosphopeptide derived from the region of EGFR that contains tyrosine 845.

  • Positive control
    • Human Epidermoid Carcinoma (A431) cells and cortic smooth muscle cells.

Properties

Applications

Our Abpromise guarantee covers the use of ab5636 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF
WB
ICC
  • Application notesICC: Use at an assay dependent dilution.
    ICC/IF: 1/50 (PMID 19147829).
    WB: Use at a concentration of 0.1 - 1.0 µg/ml. Detects a band of approximately 185 kDa.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionReceptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.
      Isoform 2 may act as an antagonist of EGF action.
    • Tissue specificityUbiquitously expressed. Isoform 2 is also expressed in ovarian cancers.
    • Involvement in diseaseDefects in EGFR are associated with lung cancer (LNCR) [MIM:211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.
    • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
      Contains 1 protein kinase domain.
    • Post-translational
      modifications
      Phosphorylation at Ser-695 is partial and occurs only if Thr-693 is phosphorylated. Phosphorylation at Thr-678 and Thr-693 by PRKD1 inhibits EGF-induced MAPK8/JNK1 activation. Dephosphorylation by PTPRJ prevents endocytosis and stabilizes the receptor at the plasma membrane. Autophosphorylation at Tyr-1197 is stimulated by methylation at Arg-1199 and enhances interaction with PTPN6. Autophosphorylation at Tyr-1092 and/or Tyr-1110 recruits STAT3.
      Monoubiquitinated and polyubiquitinated upon EGF stimulation; which does not affect tyrosine kinase activity or signaling capacity but may play a role in lysosomal targeting. Polyubiquitin linkage is mainly through 'Lys-63', but linkage through 'Lys-48', 'Lys-11' and 'Lys-29' also occur. Deubiquitinated by OTUD7B, preventing degradation.
      Methylated. Methylation at Arg-1199 by PRMT5 positively stimulates phosphorylation at Tyr-1197.
    • Cellular localizationSecreted and Cell membrane. Endoplasmic reticulum membrane. Golgi apparatus membrane. Nucleus membrane. Endosome. Endosome membrane. In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER. Endocytosed upon activation by ligand.
    • Information by UniProt
    • Database links
    • Alternative names
      • Avian erythroblastic leukemia viral (v erb b) oncogene homolog antibody
      • Avian erythroblastic leukemia viral (verbb) oncogene homolog antibody
      • Cell growth inhibiting protein 40 antibody
      • Cell proliferation inducing protein 61 antibody
      • EGF R antibody
      • EGFR antibody
      • EGFR antibody
      • EGFR_HUMAN antibody
      • Epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog) antibody
      • Epidermal growth factor receptor (erythroblastic leukemia viral (v erb b) oncogene homolog avian) antibody
      • Epidermal growth factor receptor antibody
      • erbb 1 antibody
      • Erbb antibody
      • Erbb1 antibody
      • ERBB1 antibody
      • Errp antibody
      • HER1 antibody
      • mENA antibody
      • Oncogene ERBB antibody
      • PIG61 antibody
      • Proto-oncogene c-ErbB-1 antibody
      • Receptor tyrosine protein kinase ErbB 1 antibody
      • Receptor tyrosine protein kinase ErbB1 antibody
      • Receptor tyrosine-protein kinase ErbB-1 antibody
      • Urogastrone antibody
      • wa2 antibody
      • Wa5 antibody
      see all

    Anti-EGFR (phospho Y845) antibody images

    • Peptide Competition: Extracts prepared from A431 cells stimulated with EGF were resolved by SDS-PAGE on a 10% polyacrylamide gel and transferred to nitrocellulose. Membranes were blocked with a 5% BSA TBST buffer overnight at 4°C, then incubated with 0.40 µg/mL ab5636 antibody, for two hours at room temperature in a 3% BSA-TBST buffer, following its prior incubation with: no peptide (1), the phosphopeptide immunogen (2), the non-phosphopeptide corresponding to the immunogen (3), or a generic phosphotyrosine containing peptide (4). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and bands were detected using the Tropix WesternStar method. The data show that only the phosphopeptide corresponding to ab5636 blocks the antibody signal, demonstrating the specificity of the antibody.
    • Immunodetection using ab5636 in cultured cortic smooth muscle cells treated with Angiotensin II.

    References for Anti-EGFR (phospho Y845) antibody (ab5636)

    This product has been referenced in:
    • Jaldety Y  et al. Sperm EGFR mediates a7 AChR activation to promote fertilization. J Biol Chem : (2012). Read more (PubMed: 22577141) »
    • Pontillo CA  et al. Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 signaling pathways and cell migration by hexachlorobenzene in MDA-MB-231 human breast cancer cell line. Toxicol Sci 120:284-96 (2011). Read more (PubMed: 21205633) »

    See all 4 Publications for this product

    Product Wall

    We have already arranged a refund for your. However, we would like to let you know that we have just received the results from the lab. We have retested the same batch you received, the protein content of this lot is 5.10 mg/ml. We assay the protei...

    Read More

    Thank you again for your patience. Regarding ab30, EGFR1 recognises the whole receptor protein rather than a truncated version. For ab5636, the synthetic peptide immunogen to produce the antibody is approximately 10 amino acid residues around EGFR [pY8...

    Read More

    Thank you for your patience. I have received the following information thus far: Ab231: In Western blotting ab231 detects a 170kDa band which corresponds to EGFR. The epitope recognized by this antibody is located on the extracellular domain of the...

    Read More

    Thank you for your patience. Regarding ab5636, the antibody has only been tested so far on cells. There was a mistake on the datasheet which I have since updated. I apologize for the inconvenience and if you have any more questions, please contact us a...

    Read More

    Thank you for your enquiry. Ab5652 has only been tested on frozen sections. I will contact you again once I have heard back from the originator of ab5636.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"